Earlier this week, President Donald Trump made a speech in New Hampshire to discuss the administration’s efforts in combatting both the opioid crisis and high drug prices. In the speech, Trump alluded to a possible press conference in the near future that would discuss potential proposals in reducing prescription drug prices.
Earlier this week, President Donald Trump made a speech in New Hampshire to discuss the administration’s efforts in combatting both the opioid crisis and high drug prices. In the speech, Trump alluded to a possible press conference in the near future that would discuss potential proposals in reducing prescription drug prices.
“We’re making medically assisted treatment more available and affordable, and we continue to increase competition and drive down drug prices…We’re going to have a major news conference, probably at the White House, in about a month, because all of you people — and I’m talking about prescription drugs, not necessarily the drugs that we’re talking about here. But we pay, as a country, so much for drugs because of the drug lobbies and other reasons, and the complexity of distribution, which is basically another term for saying, ‘How do we get more money?’” said Trump.
Drug pricing has gotten a lot of attention as of late, most recently with 9 physician groups voicing their opposition to Medicare drug pricing proposals in a joint letter sent to HHS.
Joining Trump in the conference was HHS Secretary Alex Azar, who spoke specifically about his department's efforts to bring drug prices down.
“Last year, the FDA approved more generic drugs than it ever has in its history,” said Azar. “And that brings prices down for patients, for the system, for everybody.”
However, some lawmakers have questioned Azar’s commitment to reducing drug prices. During Azar’s confirmation hearing, Kaiser Health News reported that Democrats, including Senator Ron Wyden, D-Oregon, pointed out that under Azar’s leadership, his previous company, drug maker Eli Lilly, had never authorized a decrease in a drug’s price during his tenure.
Azar also spoke to the same potential press conference that Trump had mentioned, stating that in about a month HHS will be “rolling out a whole slate of other proposals” around how drug prices are reduced and “how we bring discounts that the middlemen right now are getting; how those will go to our patients, to individuals,” said Azar.
The United States’ drug prices are among the highest in the world. “In some cases, it’s many times higher for the exact same pill…in the exact same package, made in the exact same plant. And we’re going to change that,” said Trump.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.